A practitioner asking should I offer MIC? in 2026 is implicitly asking why would I, when I can prescribe a GLP-1? The honest answers are narrower than the marketing, but they are real: Patients who cannot or will not take a GLP-1
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canadas health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system
The FDA is expected to approve retatrutide in late 2027 , with US market launch in early-to-mid 2028
Given the vitamins water-soluble nature, excess vitamin C is excreted in the urine without complications
Understanding Individual Response and Genetic Factors in GLP-1 Treatment The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609) variants that relate to GLP-1 and related signaling pathways
Consider whether side effects would impair safe feeding and caregiving, and plan for backup help if you proceed with a treatment that commonly causes GI symptoms
_750x422.jpg?1679474856766)
